Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
404-04-006 ISMRM Abstract

Revisiting the Role of Tyrosinase in Human Neuromelanin Formation Using NM-MRI in Oculocutaneous Albinism Type 1

Primary: Neuro - Parkinson's Disease
Secondary: Physics & Engineering - Multimodal
404-04-006 · Applications of QSM and Iron in the Brain · Tuesday, 12 May, 4:00 PM–5:50 PM · Ballroom East
Keywords: Parkinson's Disease Quantitative Susceptibility Mapping (QSM) Substantia Nigra Neuromelanin-Sensitive MRI R2star mapping
Accepted
Alexis BARON 1,2, Vineeth Radhakrishnan1,3, François-Xavier Lejeune4, Rahul Gaurav5, Mathieu SANTIN2,3,6, Benoit ARVEILIER7, Lluís MONTOLIU8, F. Xavier AYMERICH9, Silvia ENRIQUEZ-CALZADA9, Jorge HERNANDEZ-VARA9,10, Alex Rovira11, Javier HOYO9,10, Isabelle ARNULF3,12, Jean-Christophe Corvol2,3,13, Marie Vidailhet2,3,13, Miquel Vila9,10,14, Stéphane Lehéricy3,6,15,16,17,18
1Mov'it : Movement Investigation and Therapeuthics, Paris Brain Institute - ICM, Paris, France
2Institut du Cerveau – Paris Brain Institute – ICM, Sorbonne Université, INSERM UMR1127, CNRS 7225, Clinical Investigation Centre (CIC) Paris 75013, France
3Paris Brain Institute - ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, UMR S 1127, Paris, France
4Institut du Cerveau, Sorbonne Université, Inserm U 1127, CNR UMR 7225, Paris, France
5Mov'IT : Movement Investigation and Therapeutics, Paris Brain Institute - ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, UMR S 1127, Paris, France
6Center for Neuroimaging Research (CENIR), Paris Brain Institute, Paris, France
7INSERM U1211, University of Bordeaux-Bordeaux University Hospital, Bordeaux, France
8France, National Centre for Biotechnology (CNB-CSIC)-Centre for Biomedical Network Research on Rare Diseases (CIBERER-ISCIII), France
9Madrid, Spain. Vall d’Hebron University Hospital, Barcelona, Spain, Spain
10Vall d’Hebron Research Institute (VHIR)-Autonomous University of Barcelona (UAB), Spain
11Section of Neuroradiology and Magnetic Resonance Unit, Barcelona, Spain
12Sleep Disorders Unit, Pitié-Salpêtrière Hospital, AP-HP, Paris 75013, Paris, France
13Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris 75013, Paris, France
14Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain, Spain
15Sorbonne University, AP-HP, Paris Brain Institute – ICM, Pitié Salpêtrière University Hospital, Paris, France
16Paris Brain Institute - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne University, Paris, France
17Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, Paris, France
18Department of Neuroradiology, Pitié Salpêtrière Hospital, APHP, Paris, France
Presenting Author: Alexis BARON

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Sulzer D, Cassidy C, Horga G, et al. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. NPJ Park Dis. 2018;4:11. doi:10.1038/s41531-018-0047-3 [doi]
2. Watanabe T. Neuromelanin? MRI of catecholaminergic neurons. Brain. 2024;147(3):e24-e26. doi:10.1093/brain/awad393 [doi]
3. Cassidy CM, Zucca FA, Girgis RR, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci U S A. 2019;116(11):5108-5117. doi:10.1073/pnas.1807983116 [doi]
4. Fedorow H, Halliday GM, Rickert CH, Gerlach M, Riederer P, Double KL. Evidence for specific phases in the development of human neuromelanin. Neurobiol Aging. 2006;27(3):506-512. doi:10.1016/j.neurobiolaging.2005.02.015 [doi]
5. Thomas MG, Zippin J, Brooks BP. Oculocutaneous Albinism and Ocular Albinism Overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. University of Washington, Seattle; 1993. Accessed October 28, 2025. http://www.ncbi.nlm.nih.gov/books/NBK590568/
6. Langkammer C, Schweser F, Krebs N, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage. 2012;62(3):1593-1599. doi:10.1016/j.neuroimage.2012.05.049 [doi]
7. Gaurav R, Valabrègue R, Yahia-Chérif L, et al. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson’s disease using convolutional neural network. NeuroImage Clin. 2022;36:103250. doi:10.1016/j.nicl.2022.103250 [doi]
8. Fu G, El Jurdi R, Chougar L, et al. Projected pooling loss for red nucleus segmentation with soft topology constraints. J Med Imaging Bellingham Wash. 2024;11(4):044002. doi:10.1117/1.JMI.11.4.044002 [doi]
9. Gaurav R, Nobileau A, Chougar L, et al. Role of REM Sleep Behavior Disorder in Atypical Parkinsonism: A Locus Coeruleus-based Neuromelanin MRI Study. Sleep Med. 2022;100:S229-S230. doi:10.1016/j.sleep.2022.05.616 [doi]
10. Gaurav R, Yahia‐Cherif L, Pyatigorskaya N, et al. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson’s Disease: A Progression Marker. Mov Disord. 2021;36(7):1592. doi:10.1002/mds.28531 [doi]
11. Zucca FA, Segura-Aguilar J, Ferrari E, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol. 2017;155:96-119. doi:10.1016/j.pneurobio.2015.09.012 [doi]
12. Gaurav R, Lejeune FX, Santin MD, et al. Early brain iron changes in Parkinson’s disease and isolated rapid eye movement sleep behaviour disorder: a four-year longitudinal multimodal quantitative MRI study. Brain Commun. 2025;7(3):fcaf212. doi:10.1093/braincomms/fcaf212 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/404-04-006